Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €15.85 EUR
Change Today +0.40 / 2.59%
Volume 21.0K
As of 11:38 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

laboratorios farmaceuticos r (ROVI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - €16.76
52 Week Low
10/17/14 - €7.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

laboratorios farmaceuticos r (ROVI) Related Businessweek News

No Related Businessweek News Found

laboratorios farmaceuticos r (ROVI) Details

Laboratorios Farmaceúticos Rovi, S.A. engages in the research, development, in-licensing, manufacture, and marketing of small molecule and specialty biologic drugs in Spain and internationally. The company’s principal product is Bemiparin, a low molecular weight heparin. Its prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Hirobriz and Ulunar Breezhaler for the treatment of chronic obstructive pulmonary disease; Glufan for relieving symptoms of degenerative osteoarthritis (OA); and Corlentor for treating coronary artery disease and chronic heart failure. The company’s prescription products also include Exxiv for relieving the symptoms of OA, rheumatoid arthritis, ankylosing spondylitis,, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; Thymanax for treating depressive episodes in adults; and Volutsa for the treatment of benign prostatic hyperplasia. In addition, it offers diagnostic products, such as SonoVue for use in ultrasound imaging; Iopamiro and Iomeron radiographic contrast media for diagnosis; and Multihance and Prohance for use in diagnostic magnetic resonance imaging. Further, the company provides OTC products comprising Perspirex to control sweating from the underarms; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; ColdPack cold and hot bag for reliving pain; and Nitview Ledcomb, a product for lice and nits. Additionally, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Inversiones Clidia, S.L.

1,109 Employees
Last Reported Date: 02/25/15
Founded in 1946

laboratorios farmaceuticos r (ROVI) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €425.0K
Chairman of The Board, Chief Executive Manage...
Total Annual Compensation: €251.0K
Chief Financial Officer, Director and Member ...
Total Annual Compensation: €311.0K
Director of Corporate Development and Directo...
Total Annual Compensation: €312.0K
Compensation as of Fiscal Year 2014.

laboratorios farmaceuticos r (ROVI) Key Developments

Rovi Announces Earnings Results for the First Quarter of 2015

Rovi announced earnings results for the first quarter of 2015. For the quarter, the company reported a net profit of EUR 6.5 million (USD 7.2 million), 9% more than in the same period of 2014, supported by an increase in operating revenues from 5% to EUR 60.8 million. The gross operating result (EBITDA) improved by 7% and totaled EUR 9.6 million, while total sales of prescription pharmaceutical products rose 3% and amounted to EUR 35.6 million. Total revenues increased by 4% to EUR 61.1 million.

Laboratorios Farmaceuticos ROVI, S.A. Reports Consolidated Financial Results for the Fiscal Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015; Proposes Dividend for Fiscal 2014

Laboratorios Farmaceuticos ROVI, S.A. reported consolidated financial results for the fiscal year ended December 31, 2014. For the year, revenue was €238,047,000 against €217,587,000 for the same period of last year. Operating profit was €27,692,000 against €25,472,000 for the same period of last year. Profit before income tax was €25,634,000 against €24,251,000 for the same period of last year. Profit for the period was €24,116,000 against €23,022,000 for the same period of last year. Net cash generated from operating activities was €23,002,000 against €29,816,000 for the same period of last year. Purchases of intangible assets was €4,201,000 against €12,005,000 for the same period of last year. Purchases of property, plant and equipment was €20,853,000 against €12,678,000 for the same period of last year. The company expects operating revenue to grow from mid to high single digit for the full year of 2015, despite: a 2% contraction in the Spanish pharmaceutical market according to Farmaindustria1, and (ii) a zero to negative spending growth on medicines in Spain for the period 2014-2018 forecast by IMS Health 2.1 ROVI expects its growth drivers to be Bemiparin, the new license agreements (Volutsa, Ulunar, Hirobriz and Medikinet), its existing portfolio of specialty pharmaceuticals, contribution from launches such as Vytorin and Absorcol, new product distribution licenses and new contracts in the toll manufacturing area. Due to this positive performance, ROVI will propose to the Shareholders General Meeting a dividend of €0.1690 per share on 2014 earnings. This dividend would mean an increase of 5% compared to the dividend of €0.1612 on 2013 earnings.

Laboratorios Farmaceuticos ROVI, S.A. to Report Fiscal Year 2014 Results on Feb 26, 2015

Laboratorios Farmaceuticos ROVI, S.A. announced that they will report fiscal year 2014 results Pre-Market on Feb 26, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROVI:SM €15.85 EUR +0.40

ROVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ROVI.
View Industry Companies

Industry Analysis


Industry Average

Valuation ROVI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 24.0x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORIOS FARMACEUTICOS R, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at